The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Abiomed Inc

Nasdaq: ABMD
Last

(U.S.) $194.32

Today's change-0.59 -0.30%
Updated November 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Abiomed Inc

Nasdaq: ABMD
Last

(U.S.) $194.32

Today's change-0.59 -0.30%
Updated November 17 4:00 PM EST. Delayed by at least 15 minutes.

Abiomed Inc down (U.S.)$0.59

Abiomed Inc closed lower Friday, dropping (U.S.)$0.59 or 0.30% to (U.S.)$194.32. Shares have lost 0.46% over the last five days, but sit 2.00% below their 52-week high. This security has outperformed the S&P 500 by 53.15% during the last year.

Key company metrics

  • Open(U.S.) $194.56
  • Previous close(U.S.) $194.91
  • High(U.S.) $194.88
  • Low(U.S.) $191.44
  • Bid / Ask(U.S.) $195.25 / (U.S.) $0.00
  • YTD % change+72.45%
  • Volume448,782
  • Average volume (10-day)318,919
  • Average volume (1-month)363,670
  • Average volume (3-month)329,474
  • 52-week range(U.S.) $103.53 to (U.S.) $198.29
  • Beta0.18
  • Trailing P/E95.60×
  • P/E 1 year forward79.70×
  • Forward PEG2.85×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.03
Updated November 17 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.27%

Based on its net profit margin of 18.27%, Abiomed Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.40%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2018Q1/2018Q4/2017Q3/2017
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue133132125115
Total other revenue--------
Total revenue133132125115
Gross profit11111110596
Total cost of revenue22221919
Total operating expense101999689
Selling / general / administrative60616054
Research & development19171616
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income32332925
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax32342926
Income after tax25371515
Income tax, total8-41410
Net income25371515
Total adjustments to net income--------
Net income before extra. items25371515
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items25371515
Inc. avail. to common incl. extra. items25371515
Diluted net income25371515
Dilution adjustment--------
Diluted weighted average shares46464545
Diluted EPS excluding extraordinary itemsvalue per share0.540.820.330.34
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.540.820.330.34